Equities

Concord Biotech Ltd

CONCORDBIO:NSI

Concord Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,250.55
  • Today's Change110.55 / 5.17%
  • Shares traded451.68k
  • 1 Year change+124.83%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 11:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 16-Sep-24
Select bar for recommendation details.
Recommendations16-Sep-24
Buy1
Outperform0
Hold1
Sell1
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Concord Biotech Ltd have a median target of 1,920.00, with a high estimate of 1,950.00 and a low estimate of 1,480.00. The median estimate represents a -15.01% decrease from the last price of 2,259.10.
High-13.7%1,950.00
Med-15.0%1,920.00
Low-34.5%1,480.00

Dividends

In 2024, Concord Biotech Ltd reported a dividend of 8.75 INR. The 2 analysts covering the company expect dividends of 10.05 INR for the upcoming fiscal year, an increase of 14.86%.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Aug 09, 2024, Concord Biotech Ltd reported 1st quarter 2025 earnings of 5.70 per share.
Average growth rate+7.40%
Concord Biotech Ltd reported annual 2024 earnings of 29.45 per share on May 23, 2024.
More ▼

Revenue history & estimates in INR

Concord Biotech Ltd had 1st quarter 2025 revenues of 2.16bn. This missed the 2.23bn consensus estimate of the 2 analysts following the company. This was 10.77% above the prior year's 1st quarter results.
Average growth rate+6.64%
Concord Biotech Ltd had revenues for the full year 2024 of 10.17bn. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.